Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2001, for eXegenics Inc. (formerly CytoClonal Pharmaceutics Inc.). The company is a biotechnology firm focused on drug creation technologies, specifically the Quantum Core Technology (QCT) and OASIS platforms. During the quarter, the company underwent a strategic reorganization, terminating non-strategic projects, restructuring its scientific leadership, and announced a name change effective October 24, 2001.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2001 | Nine Months Ended Sep 30, 2001 |
|---|---|---|
| Revenue | $333,000 | $1,000,000 |
| Net Loss | $(2,752,000) | $(7,040,000) |
| Net Loss Attributable to Common Shareholders | $(2,752,000) | $(7,220,000) |
| Loss Per Share (Basic & Diluted) | $(0.17) | $(0.45) |
| Cash and Cash Equivalents | $19,137,000 | N/A |
| Investments | $10,030,000 | N/A |
| Total Current Liabilities | $3,148,000 | N/A |
| Accumulated Deficit | $(36,574,000) | N/A |
Cash Flow (Nine Months Ended Sep 30, 2001):
- Net cash used in operating activities: $(4,692,000)
- Net cash used in investing activities: $(10,633,000)
- Net cash used in financing activities: $(946,000)
Material Changes Versus Prior Period
- Revenue Growth: Revenue increased to $333,000 for the quarter (from $67,000 in 2000) and $1,000,000 for the nine-month period (from $754,000 in 2000), driven by licensing and R&D payments from the Bristol-Myers Squibb (BMS) agreement.
- Expense Increases: Operating expenses rose significantly. Research and Development (R&D) expenses increased to $1,106,000 for the quarter (from $891,000) due to additional scientific staff and lab activities. General and Administrative (G&A) expenses jumped to $2,268,000 (from $1,662,000), primarily due to a $765,000 expense recognized for resolving outstanding disputes.
- Liquidity Decline: Cash and cash equivalents decreased from $35,408,000 at year-end 2000 to $19,137,000 at September 30, 2001. This reduction was driven by operating losses, the purchase of $10,030,000 in marketable securities, and treasury stock purchases.
- Interest Income: Interest income decreased to $289,000 for the quarter (from $529,000) due to lower cash balances available for investment and declining interest rates.
Guidance, Outlook, and Risks
Strategic Outlook: Management has refocused the company on two core drug creation platforms (QCT and OASIS) and the BMS paclitaxel program. Non-strategic projects (e.g., Gaucher's Disease, Polycystic Kidney Disease) have been terminated for potential out-licensing. The company plans to introduce QCT to the pharmaceutical industry and accelerate OASIS commercialization.
Liquidity Position: Management believes current cash and equivalents ($19.1 million) are sufficient to fund operations through December 31, 2002. However, there is no assurance that future financing will be available on acceptable terms if needed after that date.
Risks and Contingencies:
- Dispute Resolution: The company reserved $1,165,000 in September 2001 to resolve disputes, with $765,000 recognized as an expense in Q3 and $400,000 used to purchase treasury stock as part of the settlement.
- Restructuring: Approximately $560,000 in restructuring costs were recognized, including severance packages.
- Accounting Changes: The company is evaluating the impact of new FASB standards (No. 142 and No. 144) regarding goodwill and asset impairment, effective for fiscal years beginning after December 15, 2001.
Key Facts for Investor Verification
- Settlement Payment: Verify the October 2001 payment of $1,165,000 to resolve disputes and the subsequent purchase of 100,000 shares of common stock and warrants.
- Revenue Concentration: Confirm the status and future milestone payments of the Bristol-Myers Squibb collaborative agreement, which is the primary revenue source.
- Cash Burn Rate: Assess the sustainability of the current cash position given the net cash burn of approximately $16.3 million over the nine-month period.
- Strategic Pivot: Monitor the progress of the divestment of non-strategic projects and the commercialization timeline for the QCT and OASIS platforms.
- Stock-Based Compensation: Review the impact of deferred stock-based compensation and the sale of treasury stock to the CEO on future equity dilution.